Everolimus plus trastuzumab and vinorelbine for trastuzumabresistant, taxane-pretreated, HER2+advanced breast cancer: Overall survival results from BOLERO-3
Jappe, A.; Ozguroglu, M.; Zhang, Y.; Pacaud, L. B.; Taran, T.; Isaacs, C.; O'Regan, R.; Xu, B.; Masuda, N.; Arena, F.; Yap, Y-S; Papal, Z.; Lang, I.; Armstrong, A.; Lerzo, G.; White, M.; Shen, K.